Polycystic ovary syndrome (PCOS) stands as a complex and prevalent endocrine disorder, profoundly impacting women throughout their reproductive years. Its hallmark lies in the intricate interplay of hormonal imbalances, primarily characterized by elevated androgen levels, which subsequently trigger a diverse array of clinical manifestations. These manifestations span from disruptive menstrual irregularities, such as oligomenorrhea or amenorrhea, to the visible signs of hyperandrogenism, including hirsutism, acne, and androgenic alopecia. Furthermore, PCOS extends its reach beyond reproductive health, significantly influencing metabolic functions by fostering insulin resistance, thereby escalating the risk of type 2 diabetes, dyslipidemia, and cardiovascular complications. Adding to the syndrome’s complexity are the significant psychological ramifications, often leading to increased susceptibility to anxiety, depression, and a diminished sense of self-worth. The diagnostic approach to PCOS hinges on the Rotterdam criteria, which mandates the presence of at least two of the following: oligo- or anovulation, clinical or biochemical evidence of hyperandrogenism, and the characteristic polycystic ovarian morphology as visualized through ultrasound. In terms of management, a multifaceted strategy is imperative, encompassing lifestyle modifications to mitigate insulin resistance, alongside pharmacological interventions tailored to address specific symptoms, such as hormonal therapies to regulate menstruation and antiandrogens to counteract hyperandrogenism. For women grappling with fertility challenges, assisted reproductive technologies offer viable pathways to conception. Thus, a comprehensive and individualized approach, integrating medical, lifestyle, and psychological considerations, is crucial for effectively managing PCOS and enhancing the overall well-being of affected individuals.